Last reviewed · How we verify

Agrylin — Competitive Intelligence Brief

Agrylin (ANAGRELIDE) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platelet-reducing Agent. Area: Oncology.

marketed Platelet-reducing Agent cGMP-inhibited 3',5'-cyclic phosphodiesterase A Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Agrylin (ANAGRELIDE) — Takeda. Agrylin works by inhibiting an enzyme that regulates platelet production, leading to a decrease in platelet count.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Agrylin TARGET ANAGRELIDE Takeda marketed Platelet-reducing Agent cGMP-inhibited 3',5'-cyclic phosphodiesterase A 1997-01-01
Pletal CILOSTAZOL Otsuka marketed Phosphodiesterase 3 Inhibitor [EPC] cGMP-inhibited 3',5'-cyclic phosphodiesterase A 1999-01-01
Cartonic amrinone Sanofi marketed amrinone cGMP-inhibited 3',5'-cyclic phosphodiesterase A 1984-01-01
Pletal Pletal Otsuka America Pharmaceutical marketed Cytochrome P450 2C9, cGMP-inhibited 3',5'-cyclic phosphodiesterase A, cGMP-inhibited 3',5'-cyclic phosphodiesterase B

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platelet-reducing Agent class)

  1. Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Agrylin — Competitive Intelligence Brief. https://druglandscape.com/ci/anagrelide. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: